ArticlePloS one2025
Effectiveness of the Pfizer-BioNTech (BNT162b2) vaccine against the omicron variant of SARS-CoV-2 among adults aged 50 and above: A case-control study in Lebanon, June 2022.
Article in PloS one, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The emergence of the novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and the subsequent coronavirus disease 2019 (COVID-19) pandemic with the continuous evolution of the virus into variants such as Alpha, Beta, Delta, Omicron and others necessitates an on-going surveillance and evaluation of vaccine effectiveness (VE).This study focuses on assessing the real-world performance of the Pfizer-BioNTech (BNT162b2) vaccine against the Omicron variant. This study employs a test-negative, case-control design, a methodology commonly utilized for estimating the VE in influenza studies. It evaluates SARS-CoV-2 test results in individuals aged 50 and older who had influenza-like illness (ILI) or COVID-like illness (CLI) symptoms and presented to the sentinel sites, classifying positive cases as "cases" and negative as "controls." Data collection was done through a standardized questionnaire administered by the Epidemiological Surveillance Unit (ESU) COVID-19 team via phone interviews. Logistic regression analysis was performed to measure the association, taking into account all confounding factors. The results indicate a 14% VE against contracting the disease among fully vaccinated individuals. Factors such as age and underlying conditions significantly influenced VE. The findings of this study highlight the effectiveness of the Pfizer-BioNTech (BNT162b2) vaccine in reducing the odds of symptomatic COVID-19, particularly by decreasing the prevalence of key symptoms such as fever, cough, myalgia, and loss of taste or smell. Breakthrough infections still occurred, indicating that while the vaccine reduces symptom severity, it may not fully prevent infection This VE is lower compared to previous variants, indicating potential challenges in vaccine efficacy. The study underscores the need for an on-going monitoring and potential booster doses to enhance protection, especially against evolving variants like Omicron.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.